source
- Samsung Biologics to acquire Swiss CDMO PolyPeptide for $1.8 billion, entering peptide API marketSamsung Biologics announced a plan to purchase Swiss contract development and manufacturing organization PolyPeptide for $1.8 billion in cash. The acquisition will extend Samsung Biologics' manufa…
- Tempus AI to acquire cancer test maker Personalis for $1.5 billionTempus AI announced it will buy Personalis, a Fremont-based company that offers a molecular residual disease test for cancer, in a deal valued at $1.5 billion. The acquisition is expected to expan…